Ravulizumab — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

6 Recruiting

9 Completed trials

5 Sponsors

15 Countries

Phase III

Phase II/III

Phase III: 10 Phase II/III: 2 Phase II: 1 Phase III/IV: 1 Phase IV: 1

Oversight events:

1 corrective measure across 1 trial

View oversight register →

Indications tested

IgA nephropathy 2 Paroxysmal nocturnal haemoglobinuria 1 Neuromyelitis optica spectrum disorder 1 Myasthenia gravis 1 Lupus nephritis 1 Thrombotic microangiopathy 1

Sponsors using this IMP

Alexion Pharmaceuticals Inc. 11 Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre 1 Kyverna Therapeutics Inc. 1 Radboud universitair medisch centrum Stichting 1 Regeneron Pharmaceuticals Inc. 1

All trials

15 total

A Phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicit… Recruiting

2022-501882-29-00 Phase III 4 countries Alexion Pharmaceuticals Inc.
Phase 3 Study of Ravulizumab versus Placebo in Adult Participants at High Risk of DGF after Kidney Transplantation (AWAKE) Recruiting

2024-517568-48-00 Phase III 8 countries Alexion Pharmaceuticals Inc.
A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatri… Recruiting

2024-520167-13-00 Phase III 2 countries Alexion Pharmaceuticals Inc.
Ravulizumab dose optimization Recruiting

2024-519207-10-00 Phase IV 1 country Radboud universitair medisch centrum Stichting
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting

2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.
Clinical study testing the efficacy and safety of Ravulizumab in pediatric patients with NMOSD Recruiting

2023-508534-33-00 Phase II/III 3 countries Alexion Pharmaceuticals Inc.
A study to determine if ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy (IgAN) Ended

2023-507851-31-00 Phase III 12 countries Alexion Pharmaceuticals Inc.
A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTERO… Ended

2024-512154-24-00 Phase III/IV 1 country Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre
A Long term Safety and Efficacy Study of Danicopan as an Add-on Therapy to C5i in Patients with PNH. Ended

2023-504867-18-00 Phase III 6 countries Alexion Pharmaceuticals Inc.
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients with Paroxysmal Nocturnal… Ended

2023-509657-31-00 Phase III 6 countries Regeneron Pharmaceuticals Inc.
ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney … Ended

2022-501802-36-00 Phase III 8 countries Alexion Pharmaceuticals Inc.
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-507977-16-00 Phase II 7 countries Alexion Pharmaceuticals Inc.
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 mo… Ended

2023-507850-33-00 Phase III 4 countries Alexion Pharmaceuticals Inc.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thro… Ended

2023-510107-22-00 Phase III 9 countries Alexion Pharmaceuticals Inc.
A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab… Ended

2022-502335-19-00 Phase III 2 countries Alexion Pharmaceuticals Inc.

Showing 1–15 of 15 trials

← All drugs A–Z